Antibody-Mediated Nanodrug of Proteasome Inhibitor Carfilzomib Boosts the Treatment of Multiple Myeloma
Source : https://pubmed.ncbi.nlm.nih.gov/37801632/
Multiple myeloma (MM) is the second most common hematological malignancy. For relapsed and refractory MM, a proteasome inhibitor, carfilzomib (CFZ), has become one of the few clinical options. CFZ suffers,...
The antibody-targeted nanodelivery of a proteasome inhibitor appears to be an appealing strategy to treat multiple myeloma.
Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/ Refractory Multiple Myeloma
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723015816?via=ihub
Despite its promising outcome, anti-BCMA CAR-T is the most expensive myeloma treatment that has ever been developed, and its cost-effectiveness is an ...
Although anti-BCMA CAR-T can be cost-effective even under current pricing, a high long-term PFS is necessary.
Significance of Alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
Source : https://pubmed.ncbi.nlm.nih.gov/37777383/
Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM.
Our results suggest that the ALP levels after CAR-T therapy could serve as a suitable biomarker for monitoring CAR-T cell proliferation, CRS grading, and prognosis in patients with MM.
Radiation therapy as bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy
Source : https://pubmed.ncbi.nlm.nih.gov/37778534/
Radiation therapy (RT) may play an important role prior to and following BCMA-targeted CAR T-cell therapy in multiple myeloma (MM). We report a series of 13 patients: 5 patients received...
The RT in-field local control rate was 100%, with a median follow-up after each RT course of 7.3 months. RT as a bridging and salvage strategy is safe, feasible, and offers excellent local control in MM patients treated with CAR T-cell therapy.
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience - Targeted Oncology
Source : https://link.springer.com/article/10.1007/s11523-023-01001-4
Background Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or at a subcutaneous fixed...
Subcutaneous daratumumab was safe in a real-life setting including patients with severe renal failure and advanced disease. However, further studies on larger and prospective cohorts are required to confirm our real-life observations.